NON-alcoholic fatty liver disease (NAFLD) – an accumulation of excess fat in the liver of people who drink little or no alcohol – is the third most common cause of premature death in the UK and a disease that affects a quarter of the world’s population.
It is strongly linked to type II diabetes and there is no approved treatment, but Cambridge-based Eagle Genomics, along with the Stratified Medicine Scotland Innovation Centre (SMS-IC), is hoping to help reduce deaths with early recognition of the disease, monitoring its progression and developing an effective treatment.
The two recently shared a £1.7 million grant from the UK innovation agency Innovate UK for a project that could help bring about such developments.
Eagle is a software company and its cloud-based e[automateddatascientist] platform, which is also being used in Europe and the US, will play a central role in helping to develop new tests and treatments for NAFLD.
The company’s CEO, Abel Ureta-Vidal, told The National: “We’ll be working with SMS-IC to deploy our platform to do data management for translational research, basically analysing and managing data from patients to better understand a specific disease.
“We are working on NAFLD, which is a big killer and we expect to be recruiting about 2000 patients over the next few years in Scotland to do that.
“It is a big project – not so much in terms of patients – but in Scotland access to patient data is great.
“And when you start grouping together hundreds, thousands, tens of thousands of patient records to get a global picture of a specific disease you need very good software to be able to do it in a scalable and robust way.”
The funding will help develop SteatoSITE, a data commons, or shared virtual space where biomedical research scientists can work with data and analytical tools.
As more data is added, it will evolve into a smarter, more comprehensive knowledge system that will assist important discoveries in chronic liver disease and increase the success of treatments.
Ureta-Vidal said Eagle’s interaction with the innovation centre had triggered interest in his own firm from other companies.
“Since we started putting the bid together last autumn there has been interest for pharma companies joining the consortium, which is good because it exposes the access to patient data for research and for us it’s important because these are potential customers for us as well.
“For us we are not just developing a platform for that disease. The idea of the software platform is to be generic and to be able to configure it for different diseases.
“What we can offer in this project will be a demonstrator of how it can be used to gain new insights and how we can apply it to other diseases.
“We were due to meet everyone from SMS-IC at the Life Sciences dinner earlier this year but that was postponed because of bad weather. It has been rescheduled for next month and we expect to meet them all face to face then.”
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here